集团起诉CMS阻止大麻产品进入医疗保险模式. Group sues CMS to block hemp products in Medicare care models.

由MMJ国际控股公司领导的一组在华盛顿特区提起联邦诉讼,试图阻止医疗保险和医疗补助服务中心 (CMS) 的计划,该项目包括大麻衍生类大麻素产品在与医疗保健相关的护理模式中. A group led by MMJ International Holdings filed a federal lawsuit in Washington, D.C., seeking to block the Centers for Medicare & Medicaid Services' (CMS) program that includes hemp-derived cannabinoid products in Medicare-connected care models. 诉讼人认为CMS绕过了联邦法律和FDA的批准程序, 为未经批准的产品创造了一条途径, 这可能会损害受监管疗法的发展. The plaintiffs argue CMS bypassed federal law and the FDA's approval process, creating a pathway for non-approved products that could harm the development of regulated therapies. 他们要求法院发出暂停该计划的初步禁令, 并恢复之前的监管现状. They are asking the court to issue a preliminary injunction halting the program and restore the prior regulatory status quo.